Patents Examined by George W Kosturko
  • Patent number: 12006313
    Abstract: A 7-(4-((5-(benzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anticancer and/or anti-inflammatory agent.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: June 11, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11987591
    Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: May 21, 2024
    Assignee: Sumitomo Pharma America, Inc.
    Inventors: Andrea Bauer, Nandkumar Nivritti Bhogle, Xiaoxia Chen, Shahla Jamzad, Robert Joseph Prytko, Kostas Saranteas, Michael Joseph Sizensky, Harold Scott Wilkinson, Haitao Zhang
  • Patent number: 11964956
    Abstract: Disclosed are compounds and compositions that modulate cannabinoid receptors, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors. This disclosure is directed to methods of treating cannabinoid dependence, neuropathy, inflammation, glaucoma, a neurodegenerative disorder, a motor function disorder, a gastrointestinal disorder, hypothermia, emesis, loss of appetite, or anorexia associated with AIDS.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: April 23, 2024
    Assignee: Northeastern University
    Inventors: Alexandros Makriyannis, Spyridon P. Nikas, Ganeshsingh A. Thakur, Rishi Sharma, Shashank Kulkarni
  • Patent number: 11957645
    Abstract: The present invention provides a method for safe and efficacious administration of esketamine.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: April 16, 2024
    Assignee: CLEXIO BIOSCIENCES LTD.
    Inventors: Elena Kagan, Gina Pastino
  • Patent number: 11952384
    Abstract: The present application relates to an anti-tumor compound and a preparation method and use thereof, and in particular to a compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof.
    Type: Grant
    Filed: December 28, 2022
    Date of Patent: April 9, 2024
    Assignee: DUALITY BIOLOGICS (SUZHOU) CO., LTD.
    Inventors: Yu Zhang, Zhongyuan Zhu, Haiqing Hua, Bing Li, Jian Li, Shengchao Lin, Xi Li, Hongxia Shen
  • Patent number: 11944617
    Abstract: Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein. Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant. Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: April 2, 2024
    Assignee: Corcept Therapeutics Incorporated
    Inventors: Hazel Hunt, Joseph Custodio
  • Patent number: 11944615
    Abstract: Provided are methods of sensitizing LKB1/STK11 deficient cancers to immune therapy. A method for treatment for LKB1/STK11 deficient cancers is provided comprising administration of inhibitor or inhibitors of one or more of NAMPT, CD38, SHP2, CXCR1/2, HDAC4 and PARP in combination with immunotherapy.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: April 2, 2024
    Assignee: New York University
    Inventors: David Peng, Kwok-Kin Wong, Jiehui Deng
  • Patent number: 11944094
    Abstract: A seed germination activator for control of broomrape includes butylisobutylphthalate (hereinafter “BIP”). A biocontrol composition includes BIP and at least two nonionic surfactants for administration in irrigation water. Methods of controlling broomrape may include administering the biocontrol composition comprising BIP in the irrigation water prior to planting crops.
    Type: Grant
    Filed: August 17, 2023
    Date of Patent: April 2, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Khaled Mohamed Amen Ramadan, Hossam El-Din Saad El-Beltagi, Hani Saber Sayed Saudy, Ahmed Zein El-Abdein Abdel Azeiz
  • Patent number: 11944625
    Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: April 2, 2024
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: James Bradner, Jun Qi, Dennis Buckley, Leonard I. Zon, Elizabeth Macari
  • Patent number: 11937600
    Abstract: A seed germination activator for control of broomrape includes butylisobutylphthalate (hereinafter “BIP”). A biocontrol composition includes BIP and at least two nonionic surfactants for administration in irrigation water. Methods of controlling broomrape may include administering the biocontrol composition comprising BIP in the irrigation water prior to planting crops.
    Type: Grant
    Filed: March 14, 2023
    Date of Patent: March 26, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Khaled Mohamed Amen Ramadan, Hossam El-Din Saad El-Beltagi, Hani Saber Sayed Saudy, Ahmed Zein El-Abdein Abdel Azeiz
  • Patent number: 11938109
    Abstract: Described is a method for the preparation of an oral levothyroxine composition, comprising the steps of combining levothyroxine or a salt thereof, a water-miscible organic solvent or a sugar alcohol and water, adjusting the pH to at least 8 providing a basic aqueous medium, dissolving the levothyroxine in the basic aqueous medium to yield a levothyroxine solution, and lowering the pH of the levothyroxine solution to between 3.5-4.9. also described is an oral levothyroxine composition obtainable by the said method and its use as a medicament.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: March 26, 2024
    Assignee: EMP LEVO US B.V.
    Inventors: Yannis Psarrakis, Konstantinos Lioumis
  • Patent number: 11938115
    Abstract: The present disclosure relates to a benzoselenophene-based compound, a method of preparing the benzoselenophene-based compound, and a pharmaceutical composition and antibody-drug conjugate including the benzoselenophene-based compound.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: March 26, 2024
    Assignee: AIMED BIO INC.
    Inventors: Dongyeol Lim, Min Cheol Kim, Amol Mhetre, Do-Hyun Nam
  • Patent number: 11938129
    Abstract: The technology described herein relates to methods and compositions to prevent or treat vascular disease by targeting the epigenetic regulation of gene expression of vascular smooth muscle cell cytoskeletal proteins.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: March 26, 2024
    Inventors: Mark E. Lindsay, Christian Lacks Lino Cardenas, Rajeev Malhotra
  • Patent number: 11939340
    Abstract: The disclosure is directed to compounds of Formula I pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: March 26, 2024
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Jincong Zhuo, Xiaowei Wu, Katarina Rohlfing, Andrew Combs
  • Patent number: 11918551
    Abstract: Methods of treating a seizure disorder with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of a seizure disorder. Methods of treating Prader-Willi syndrome with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of Prader-Willi syndrome.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: March 5, 2024
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During
  • Patent number: 11918552
    Abstract: The present invention relates to N-acetylcysteine for the use in the treatment of bacterial infections caused by a pathogen selected from Burkholderia cepacia complex (BCC) and Stenotrophomonas maltophilia (S. maltophilia) strains.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: March 5, 2024
    Assignee: Zambon S.P.A.
    Inventors: Gian Maria Rossolini, Lucia Pallecchi, Francesco Sergio
  • Patent number: 11919871
    Abstract: A 3-(3-chlorophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: March 5, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11918587
    Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a RAF inhibitor. Some embodiments comprise combination therapy featuring the RAF inhibitor with at least one oncology therapeutic agent.
    Type: Grant
    Filed: April 6, 2023
    Date of Patent: March 5, 2024
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Aleksandra Franovic, Eric Martin, Nichol L. G. Miller, Eric Murphy, Richard Thomas Williams, Ken Kobayashi
  • Patent number: 11913077
    Abstract: A method of treating a cancer in a patient includes obtaining a sample from the patient, using a C-circle assay to detect a presence of an alternative lengthening of telomeres (ALT) phenotype in the sample, and administering an effect amount of at least one of PRIMA-1 or APR-246 to the patient.
    Type: Grant
    Filed: March 9, 2019
    Date of Patent: February 27, 2024
    Assignee: Texas Tech University System
    Inventors: Charles Patrick Reynolds, Balakrishna Koneru, Shawn Macha
  • Patent number: 11911356
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for the treatment of cancer characterized by TERT and BRAF mutations. In a specific embodiment, a method for treating a mutant telomerase reverse trancriptase (TERT) enzyme-associated cancer in a subject comprises the step of administering to the subject an anti-cancer agent that inhibits one or more of FOS, GABPB, the formation of the GABPA-GABPB complex or the binding of the GABPA-GABPB complex to a mutant TERT promoter.
    Type: Grant
    Filed: December 22, 2018
    Date of Patent: February 27, 2024
    Assignee: The Johns Hopkins University
    Inventors: Michael Mingzhao Xing, Rengyun Liu